G-protein inactivator RGS6 mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin

Jianqi Yang, Biswanath Maity, Jie Huang, Zhan Gao, Adele Stewart, Robert M. Weiss, Mark Anderson, Rory A. Fisher

Research output: Contribution to journalArticle

Abstract

Clinical use of the widely used chemotherapeutic agent doxorubicin is limited by life-threatening cardiotoxicity. The mechanisms underlying doxorubicin-induced cardiomyopathy and heart failure remain unclear but are thought to involve p53-mediated myocardial cell apoptosis. The tripartite G-protein inactivating protein RGS6 has been implicated in reactive oxygen species (ROS) generation, ATM/p53 activation, and apoptosis in doxorubicin-treated cells. Thus, we hypothesized that RGS6, the expression of which is enriched in cardiac tissue, might also be responsible for the pathologic effects of doxorubicin treatment in heart. In this study, we show that RGS6 expression is induced strongly by doxorubicin in the ventricles of mice and isolated ventricular myocytes via a posttranscriptional mechanism.While doxorubicintreated wild-type (WT) mice manifested severe left ventricular dysfunction, loss of heart and body mass, along with decreased survival 5 days after doxorubicin administration, mice lacking RGS6 were completely protected against these pathogenic responses. Activation of ATM/p53 apoptosis signaling by doxorubicin in ventricles of WT mice was also absent in their RGS6 -/- counterparts. Doxorubicin-induced ROS generation was dramatically impaired in both the ventricles and ventricular myocytes isolated from RGS6-/- mice, and the apoptotic response to doxorubicin in ventricular myocytes required RGS6-dependent ROS production. These results identify RGS6 as an essential mediator of the pathogenic responses to doxorubicin in heart, and they argue that RGS6 inhibition offers a rational means to circumvent doxorubicin cardiotoxicity in human patients with cancer.

Original languageEnglish (US)
Pages (from-to)1662-1667
Number of pages6
JournalCancer Research
Volume73
Issue number6
DOIs
StatePublished - Mar 15 2013
Externally publishedYes

Fingerprint

Cardiomyopathies
GTP-Binding Proteins
Doxorubicin
Apoptosis
Muscle Cells
Reactive Oxygen Species
Left Ventricular Dysfunction
Heart Failure
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yang, J., Maity, B., Huang, J., Gao, Z., Stewart, A., Weiss, R. M., ... Fisher, R. A. (2013). G-protein inactivator RGS6 mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin. Cancer Research, 73(6), 1662-1667. https://doi.org/10.1158/0008-5472.CAN-12-3453

G-protein inactivator RGS6 mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin. / Yang, Jianqi; Maity, Biswanath; Huang, Jie; Gao, Zhan; Stewart, Adele; Weiss, Robert M.; Anderson, Mark; Fisher, Rory A.

In: Cancer Research, Vol. 73, No. 6, 15.03.2013, p. 1662-1667.

Research output: Contribution to journalArticle

Yang, Jianqi ; Maity, Biswanath ; Huang, Jie ; Gao, Zhan ; Stewart, Adele ; Weiss, Robert M. ; Anderson, Mark ; Fisher, Rory A. / G-protein inactivator RGS6 mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin. In: Cancer Research. 2013 ; Vol. 73, No. 6. pp. 1662-1667.
@article{7cde2ac7bd244f9b83dcdcd07419dd6e,
title = "G-protein inactivator RGS6 mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin",
abstract = "Clinical use of the widely used chemotherapeutic agent doxorubicin is limited by life-threatening cardiotoxicity. The mechanisms underlying doxorubicin-induced cardiomyopathy and heart failure remain unclear but are thought to involve p53-mediated myocardial cell apoptosis. The tripartite G-protein inactivating protein RGS6 has been implicated in reactive oxygen species (ROS) generation, ATM/p53 activation, and apoptosis in doxorubicin-treated cells. Thus, we hypothesized that RGS6, the expression of which is enriched in cardiac tissue, might also be responsible for the pathologic effects of doxorubicin treatment in heart. In this study, we show that RGS6 expression is induced strongly by doxorubicin in the ventricles of mice and isolated ventricular myocytes via a posttranscriptional mechanism.While doxorubicintreated wild-type (WT) mice manifested severe left ventricular dysfunction, loss of heart and body mass, along with decreased survival 5 days after doxorubicin administration, mice lacking RGS6 were completely protected against these pathogenic responses. Activation of ATM/p53 apoptosis signaling by doxorubicin in ventricles of WT mice was also absent in their RGS6 -/- counterparts. Doxorubicin-induced ROS generation was dramatically impaired in both the ventricles and ventricular myocytes isolated from RGS6-/- mice, and the apoptotic response to doxorubicin in ventricular myocytes required RGS6-dependent ROS production. These results identify RGS6 as an essential mediator of the pathogenic responses to doxorubicin in heart, and they argue that RGS6 inhibition offers a rational means to circumvent doxorubicin cardiotoxicity in human patients with cancer.",
author = "Jianqi Yang and Biswanath Maity and Jie Huang and Zhan Gao and Adele Stewart and Weiss, {Robert M.} and Mark Anderson and Fisher, {Rory A.}",
year = "2013",
month = "3",
day = "15",
doi = "10.1158/0008-5472.CAN-12-3453",
language = "English (US)",
volume = "73",
pages = "1662--1667",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - G-protein inactivator RGS6 mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin

AU - Yang, Jianqi

AU - Maity, Biswanath

AU - Huang, Jie

AU - Gao, Zhan

AU - Stewart, Adele

AU - Weiss, Robert M.

AU - Anderson, Mark

AU - Fisher, Rory A.

PY - 2013/3/15

Y1 - 2013/3/15

N2 - Clinical use of the widely used chemotherapeutic agent doxorubicin is limited by life-threatening cardiotoxicity. The mechanisms underlying doxorubicin-induced cardiomyopathy and heart failure remain unclear but are thought to involve p53-mediated myocardial cell apoptosis. The tripartite G-protein inactivating protein RGS6 has been implicated in reactive oxygen species (ROS) generation, ATM/p53 activation, and apoptosis in doxorubicin-treated cells. Thus, we hypothesized that RGS6, the expression of which is enriched in cardiac tissue, might also be responsible for the pathologic effects of doxorubicin treatment in heart. In this study, we show that RGS6 expression is induced strongly by doxorubicin in the ventricles of mice and isolated ventricular myocytes via a posttranscriptional mechanism.While doxorubicintreated wild-type (WT) mice manifested severe left ventricular dysfunction, loss of heart and body mass, along with decreased survival 5 days after doxorubicin administration, mice lacking RGS6 were completely protected against these pathogenic responses. Activation of ATM/p53 apoptosis signaling by doxorubicin in ventricles of WT mice was also absent in their RGS6 -/- counterparts. Doxorubicin-induced ROS generation was dramatically impaired in both the ventricles and ventricular myocytes isolated from RGS6-/- mice, and the apoptotic response to doxorubicin in ventricular myocytes required RGS6-dependent ROS production. These results identify RGS6 as an essential mediator of the pathogenic responses to doxorubicin in heart, and they argue that RGS6 inhibition offers a rational means to circumvent doxorubicin cardiotoxicity in human patients with cancer.

AB - Clinical use of the widely used chemotherapeutic agent doxorubicin is limited by life-threatening cardiotoxicity. The mechanisms underlying doxorubicin-induced cardiomyopathy and heart failure remain unclear but are thought to involve p53-mediated myocardial cell apoptosis. The tripartite G-protein inactivating protein RGS6 has been implicated in reactive oxygen species (ROS) generation, ATM/p53 activation, and apoptosis in doxorubicin-treated cells. Thus, we hypothesized that RGS6, the expression of which is enriched in cardiac tissue, might also be responsible for the pathologic effects of doxorubicin treatment in heart. In this study, we show that RGS6 expression is induced strongly by doxorubicin in the ventricles of mice and isolated ventricular myocytes via a posttranscriptional mechanism.While doxorubicintreated wild-type (WT) mice manifested severe left ventricular dysfunction, loss of heart and body mass, along with decreased survival 5 days after doxorubicin administration, mice lacking RGS6 were completely protected against these pathogenic responses. Activation of ATM/p53 apoptosis signaling by doxorubicin in ventricles of WT mice was also absent in their RGS6 -/- counterparts. Doxorubicin-induced ROS generation was dramatically impaired in both the ventricles and ventricular myocytes isolated from RGS6-/- mice, and the apoptotic response to doxorubicin in ventricular myocytes required RGS6-dependent ROS production. These results identify RGS6 as an essential mediator of the pathogenic responses to doxorubicin in heart, and they argue that RGS6 inhibition offers a rational means to circumvent doxorubicin cardiotoxicity in human patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=84875475071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875475071&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-3453

DO - 10.1158/0008-5472.CAN-12-3453

M3 - Article

C2 - 23338613

AN - SCOPUS:84875475071

VL - 73

SP - 1662

EP - 1667

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 6

ER -